Tag:

Eli Lilly

Health

Insilico CEO Praises Eli Lilly as AI Leader Amid $2.75B Deal

by Chief Editor
written by Chief Editor

AI-Powered Drug Discovery: Lilly and Insilico Medicine Forge a $2.75 Billion Partnership

The pharmaceutical landscape is undergoing a seismic shift, driven by the integration of artificial intelligence (AI) into drug discovery. A recent collaboration between Eli Lilly and Insilico Medicine, valued at up to $2.75 billion, exemplifies this trend. The deal, announced on March 29, 2026, highlights the growing confidence in AI’s ability to accelerate and improve the traditionally lengthy and expensive process of bringing modern drugs to market.

The Power of Pharma.AI

Insilico Medicine, a clinical-stage biotechnology company, is leveraging its proprietary Pharma.AI platforms to identify and develop novel therapeutics. This collaboration grants Eli Lilly an exclusive worldwide license to develop, manufacture, and commercialize a portfolio of preclinical candidates discovered using Insilico’s AI engine. Alex Zhavoronkov, founder and CEO of Insilico Medicine, emphasized the company’s focus on “deep learning for end-to-end drug discovery,” enabling the identification of multi-purpose targets driving multiple diseases simultaneously.

Zhavoronkov’s Praise for Lilly: A Strategic Alignment?

Zhavoronkov has publicly expressed admiration for Eli Lilly, even citing their drug tirzepatide as “the best drug ever invented by humans.” He has consistently praised Lilly for over a year, stating that they are leaders in AI within the pharmaceutical industry. While some might view these comments as influenced by the substantial financial agreement, Zhavoronkov maintains that his positive assessment is genuine, and that Lilly is the “absolutely best partner” for the licensed candidates.

Focus on Oral Therapeutics and GLP-1 Targets

The collaboration specifically focuses on the development of novel oral therapeutics. Insilico Medicine recently out-licensed a candidate targeting GLP-1 (glucagon-like peptide-1) to an undisclosed partner, suggesting a potential area of interest within the partnership. GLP-1 receptor agonists, like Lilly’s Mounjaro and Zepbound, are used in the treatment of type 2 diabetes and obesity, representing a significant market opportunity.

The Biobuck Bonanza: Deal Terms and Implications

The deal structure includes an upfront payment of $115 million to Insilico Medicine, with the potential for an additional $2.75 billion in milestone payments tied to regulatory and commercial success. This substantial investment underscores the perceived value of Insilico’s AI capabilities and the potential for significant returns for both companies. Zhavoronkov noted that this deal is crucial for Insilico, showcasing their ability to design novel molecules in a competitive market.

Future Trends in AI-Driven Drug Discovery

This partnership is indicative of several key trends shaping the future of pharmaceutical research:

  • Increased AI Adoption: More pharmaceutical companies will integrate AI and machine learning into their drug discovery pipelines.
  • Focus on Oral Therapeutics: Oral drugs are generally preferred by patients due to convenience and cost-effectiveness, driving demand for AI-driven discovery of oral formulations.
  • Generative AI’s Role: Generative AI, as utilized by Insilico, will become increasingly important in designing novel molecules with desired properties.
  • Strategic Partnerships: Collaboration between AI-focused biotech companies and established pharmaceutical giants will become more common.
  • Personalized Medicine: AI will facilitate the development of personalized therapies tailored to individual patient characteristics.

Pro Tip:

Keep an eye on companies investing heavily in AI infrastructure and talent. These are likely to be at the forefront of the next wave of pharmaceutical innovation.

FAQ

Q: What is Pharma.AI?
A: Pharma.AI is Insilico Medicine’s suite of AI platforms designed for end-to-end drug discovery, from target identification to preclinical candidate selection.

Q: What are GLP-1 receptor agonists?
A: GLP-1 receptor agonists are a class of drugs used to treat type 2 diabetes and obesity by mimicking the effects of the naturally occurring GLP-1 hormone.

Q: What are “biobucks”?
A: “Biobucks” is a common term in the pharmaceutical industry referring to milestone payments made to biotech companies based on the achievement of specific development, regulatory, and commercial goals.

Q: What is Insilico Medicine’s role in this partnership?
A: Insilico Medicine will leverage its AI engine to discover and develop novel therapeutic candidates, which Lilly will then develop, manufacture, and commercialize.

Want to learn more about the intersection of AI and biotechnology? Explore our other articles on drug discovery and personalized medicine.

0 comments
0 FacebookTwitterPinterestEmail
Business

Ozempic Goes Generic —But Not in the US

by Chief Editor
written by Chief Editor

Ozempic’s Patent Cliff: A Global Shift in Diabetes and Weight Loss Treatment

A pivotal moment is unfolding in the pharmaceutical landscape as patent protections for semaglutide – the active ingredient in both Ozempic (for diabetes) and Wegovy (for weight loss) – expire in key global markets. This expiration, beginning Saturday, March 28, 2026, is poised to dramatically alter access to these medications, particularly in regions grappling with rising rates of obesity and diabetes.

The Democratization of Access: India Leads the Way

The initial impact will be most keenly felt in India, where generic versions of semaglutide are expected to flood the market almost immediately. Analysts predict around 50 generic manufacturers will enter India’s $60 billion pharmaceutical market within months, potentially creating a $1 billion market for semaglutide generics annually. This surge in competition is anticipated to drive down monthly costs to approximately $15, a significant reduction from current prices.

This shift isn’t limited to India. China, Canada, Brazil, Turkey and South Africa will also see patent expirations in the coming months, collectively representing approximately 40% of the world’s population. As one treatment-access advocate in Fresh Delhi noted, this will “democratize” access to drugs previously restricted to high-income countries and affluent individuals.

Impact on Novo Nordisk and the Competitive Landscape

The patent expirations represent a significant challenge for Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy. The company is already facing increased competition from Eli Lilly’s rival drugs and the emergence of gray-market compounded versions in the United States.

Novo Nordisk is responding by cutting prices in India and China, pursuing legal challenges against generics, and exploring strategies to position its original products as premium brands. However, the company’s ability to maintain market share will be tested as more affordable alternatives become available.

A Delayed Arrival of Generics in the US and Europe

While much of the world prepares for a wave of semaglutide generics, patients in the United States and most of Europe face a considerably longer wait. Patent-term extensions and other legal protections mean that true generics for Ozempic and Wegovy are unlikely to arrive until the early 2030s. This delay is drawing criticism from those who argue it will impose substantial costs on patients and taxpayers.

Beyond Diabetes: Expanding Applications and Public Health Implications

The availability of cheaper semaglutide generics has the potential to significantly impact public health, extending beyond diabetes management. Public health experts hope that lower costs will enable national health systems in middle-income countries to cover the medication more broadly, not only for diabetes but also for preventing heart attacks and strokes. Ozempic has been shown to reduce the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease.

Ozempic has demonstrated a capacity to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease.

The Rise of Oral Semaglutide

Adding another layer to the evolving landscape, Novo Nordisk has recently received FDA approval for Ozempic tablets (1.5 mg, 4 mg, and 9 mg), slated for US availability in the second quarter of 2026. This oral formulation offers a new delivery method for semaglutide, potentially increasing patient convenience and adherence.

Frequently Asked Questions

Q: What is semaglutide?
A: Semaglutide is the active ingredient in Ozempic and Wegovy, a GLP-1 receptor agonist used to treat type 2 diabetes and obesity.

Q: When will Ozempic generics be available in the US?
A: Generics are not expected to be available in the US until the early 2030s due to patent protections.

Q: What impact will generics have on the price of Ozempic?
A: Generics are expected to significantly lower the price of semaglutide, potentially reducing monthly costs to around $15 in some markets.

Q: Is Ozempic the same as Wegovy?
A: Both contain semaglutide, but Wegovy is specifically approved for weight loss at a higher dosage than Ozempic, which is approved for type 2 diabetes.

Did you know? Ozempic is a once-weekly injection, offering a convenient dosing schedule for patients with type 2 diabetes.

Pro Tip: Discuss the potential benefits and risks of semaglutide with your healthcare provider to determine if it’s the right treatment option for you.

Stay informed about the latest developments in diabetes and weight loss management. Explore our other articles for more insights and resources.

0 comments
0 FacebookTwitterPinterestEmail
Health

Retatrutide: Lilly’s Diabetes Drug Shows Significant Weight Loss & Blood Sugar Control

by Chief Editor
written by Chief Editor

Lilly’s Retatrutide: A New Era in Diabetes and Weight Management?

Eli Lilly’s investigational drug, retatrutide, is generating significant buzz after demonstrating impressive results in a late-stage trial for Type 2 diabetes. The findings, released today, suggest a potential breakthrough in managing both blood sugar and weight – a historically challenging combination for individuals with the condition.

Unprecedented Weight Loss in Diabetes Patients

Traditionally, weight loss has been more difficult to achieve for people with Type 2 diabetes compared to those without the condition. Retatrutide appears to be changing that narrative. Participants on the highest dose (12mg) of retatrutide experienced an average weight loss of 16.8%, equivalent to approximately 36.6 pounds, over 40 weeks. Even when accounting for all participants, including those who stopped treatment, weight loss remained substantial at 15.3%.

What’s particularly encouraging is that weight loss didn’t appear to plateau during the study period, suggesting continued benefits with longer-term use. This contrasts with some existing weight loss medications where individuals may experience an initial rapid loss followed by stabilization.

Significant Improvements in Blood Sugar Control

Beyond weight loss, retatrutide similarly delivered substantial improvements in glycemic control. Patients taking retatrutide saw an average reduction of 1.7% to 2.0% in HbA1C levels – a key measure of blood sugar – compared to a 0.8% reduction in the placebo group. These results are comparable to those seen with Lilly’s already popular diabetes drug, Mounjaro.

How Does Retatrutide Work?

Retatrutide is a first-in-class triple hormone receptor agonist, meaning it targets three key hormones: GIP, GLP-1 and glucagon. By activating these receptors, the drug appears to enhance insulin secretion, suppress glucagon secretion, and slow gastric emptying, leading to both improved blood sugar control and reduced appetite.

The Future of Obesity and Cardiometabolic Health

Lilly is positioning retatrutide as a potential cornerstone of its cardiometabolic health portfolio, alongside Zepbound (its blockbuster weight loss injection) and orforglipron (an upcoming oral medication). The success of retatrutide in the Type 2 diabetes trial strengthens the company’s bet on triple agonist therapies as a next-generation approach to tackling obesity and related metabolic disorders.

The implications extend beyond diabetes. Given the strong link between obesity and numerous health conditions – including heart disease, stroke, and certain cancers – effective weight management strategies are increasingly crucial for public health. Retatrutide’s potential to deliver significant and sustained weight loss could have a far-reaching impact.

What’s Next for Retatrutide?

Lilly is currently conducting additional Phase 3 clinical trials to evaluate retatrutide’s efficacy and safety in individuals with obesity or overweight and at least one weight-related medical problem. The results of these trials will be critical in determining the drug’s potential for broader approval and use.

Frequently Asked Questions

What is HbA1C?

HbA1C is a measure of your average blood sugar levels over the past 2-3 months.

What are GIP, GLP-1, and glucagon?

These are hormones that play key roles in regulating blood sugar, appetite, and metabolism.

Is retatrutide available now?

No, retatrutide is still an investigational drug and is not yet available for prescription. It is currently in clinical trials.

Pro Tip: Maintaining a healthy lifestyle, including a balanced diet and regular exercise, remains essential even with the use of medications like retatrutide.

Do you have questions about retatrutide or other diabetes treatments? Share your thoughts in the comments below!

Explore more articles on diabetes management and weight loss strategies.

0 comments
0 FacebookTwitterPinterestEmail
Health

Eli Lilly’s Zepbound: New Employer Program to Boost Access & Sales

by Chief Editor
written by Chief Editor

Eli Lilly’s Employer Connect: A New Prescription for Obesity Care Access?

Eli Lilly is tackling a critical barrier to widespread obesity treatment: access. The pharmaceutical giant has launched “Employer Connect,” a platform designed to bridge the gap between patients, employers, and independent program administrators, aiming to make medications like Zepbound more readily available to U.S. Workers.

The Challenge of Affordability and Coverage

Despite growing medical demand, a significant hurdle remains: cost and inconsistent insurance coverage. Lilly estimates that roughly half of individuals with commercial insurance face difficulties initiating or continuing obesity medication treatment. This lack of access isn’t just a patient issue; it’s a business impediment for Lilly, limiting the potential market for its drugs.

How Employer Connect Works

The Employer Connect platform facilitates direct connections between employers and over 15 independent program administrators. These administrators can then develop tailored, transparent solutions for employees seeking obesity care. A key feature is the offering of Zepbound (tirzepatide) at a list price of $449 per month for all dosages, without traditional rebates. This aims to provide employers with greater cost predictability.

Employers can choose from administrators offering basic services like enrollment and claims processing, or more comprehensive programs including telemedicine, nutritional guidance, and lifestyle support. Currently, approximately 20% of companies with over 200 employees cover GLP-1 medications for weight loss, rising to 43% for larger employers (5,000+ employees).

A Shift in Industry Approach

Experts view Employer Connect as an incremental but significant step. Previously, manufacturers and pharmacy benefit managers often opposed external discount programs. Now, GLP-1 providers are increasingly collaborating with these models to expand access. This represents a notable change in strategy.

Pro Tip: The move towards direct-to-employer platforms could reshape negotiations between pharmaceutical companies and pharmacy benefit managers, potentially leading to more transparent pricing structures.

Lilly’s Financial Momentum and Future Pipeline

Lilly’s financial performance is currently bolstered by its incretin products. In 2025, the company reported $65.2 billion in revenue (+45%) and earnings per share of $24.21 (+86%). Mounjaro and Zepbound drove much of this growth, increasing by 99% and 175% respectively.

However, this success also creates a concentration risk. Currently, these two GLP-1 products account for 56% of Lilly’s total revenue. The company is actively diversifying its pipeline with oral GLP-1 options like orforglipron, which is awaiting FDA approval, and retatrutide, currently in Phase 3 trials.

Looking Ahead: Orforglipron and Beyond

The FDA decision on orforglipron, expected in the second quarter of 2026, is a key catalyst for Lilly. International launches are planned for 2027. Phase 3 data for retatrutide will also be closely watched, as Lilly seeks to demonstrate its ability to sustain growth beyond its current GLP-1 offerings.

Lilly’s stock has experienced recent downward pressure (-4.24% in the last week). Investors will be looking for positive developments regarding orforglipron and retatrutide to reaffirm confidence in the company’s long-term growth prospects.

Frequently Asked Questions

Q: What is Zepbound?
A: Zepbound (tirzepatide) is a medication developed by Eli Lilly for weight management.

Q: What does Employer Connect aim to achieve?
A: Employer Connect seeks to improve access to obesity medications like Zepbound by connecting employers with program administrators offering affordable and comprehensive care solutions.

Q: How does the $449 price point for Zepbound work?
A: The $449 price is a list price offered through the platform, and importantly, excludes traditional rebates, providing employers with greater cost transparency.

Q: What is orforglipron?
A: Orforglipron is an oral GLP-1 medication in development by Eli Lilly, awaiting FDA approval.

Did you know? The launch of Employer Connect follows a trend of pharmaceutical companies exploring direct-to-employer models to bypass traditional pharmacy benefit managers and improve drug access.

What are your thoughts on Eli Lilly’s new platform? Share your comments below!

0 comments
0 FacebookTwitterPinterestEmail
Health

Eli Lilly’s CEO finds AI is ‘not particularly good’ at biology or chemistry problems

by Chief Editor
written by Chief Editor

The AI Revolution in Cancer Research: Hope, Hype, and the Road Ahead

The search for a cancer cure is an age-old quest, with evidence of early investigations dating back to ancient Egypt around 2600 BC, as documented by Imhotep. Today, artificial intelligence is being hailed by some as the key to finally unlocking this medical mystery.

The Promise of AI: Accelerated Discovery

Tech leaders are increasingly optimistic about AI’s potential. Google president Ruth Porat recently predicted a cancer cure within our lifetime, fueled by AI advancements. Anthropic CEO Dario Amodei describes this era as “the compressed 21st century,” suggesting AI will dramatically accelerate medical progress. This optimism has driven record levels of investment in AI, rivaling the GDP of some developed nations, exemplified by projects like the $500 billion Stargate Project announced last year.

Reality Check: AI’s Current Limitations

However, not everyone shares this unbridled enthusiasm. Eli Lilly CEO David Ricks cautions that AI is currently far from a cure. He points out that AI models are primarily trained on human language, not the complex languages of chemistry, physics, and biology. Whereas AI can predict outcomes, like the structure of proteins, Ricks argues this represents only a tiny fraction of the challenges in drug discovery.

AI Success Stories: Early Wins in Cancer Research

Despite the limitations, AI is already making significant contributions. Harvard’s Sybil AI model accurately predicted lung cancer risk within six years. Google DeepMind’s AlphaProteo has proven instrumental in designing protein binders targeting cancer-related molecules. Notably, Eli Lilly utilizes AlphaFold, another Google DeepMind AI system, demonstrating a practical application of this technology within the pharmaceutical industry.

The Future: Narrow AI and Specialized Models

Ricks believes the future lies in developing highly specialized AI models focused on narrow prediction problems. He suggests that biology doesn’t adhere to the same rules as human language, requiring tailored AI approaches. This is exemplified by Google DeepMind’s AlphaFold and AlphaProteo, which excel in specific areas of biological research. He emphasizes that we are still in the early stages of understanding the “language of biology,” comparing our current knowledge to that of a toddler.

The Stargate Project and the Race for a Cancer Vaccine

The substantial investment in AI infrastructure, such as the Stargate Project, is partly driven by the hope of creating a cancer vaccine. Oracle executive chairman Larry Ellison suggested that such a vaccine could potentially be devised within 48 hours using AI, though this remains a highly ambitious goal.

Pro Tip:

Focus on specialized AI models. The most significant breakthroughs will likely arrive from AI trained on specific biological datasets, rather than general-purpose large language models.

FAQ: AI and Cancer Research

  • Can AI cure cancer? Currently, no. AI is a powerful tool, but it’s not a standalone cure.
  • What is AlphaFold? An AI system developed by Google DeepMind that predicts protein structures.
  • Is the Stargate Project likely to succeed? It’s a significant investment, but the timeline for a cancer vaccine remains uncertain.
  • What are the limitations of AI in biology? AI models are often trained on language, not the complex systems of biology, chemistry, and physics.

Did you know? Ancient Egyptians documented human tumors as early as 2600 BC, highlighting the long history of cancer research.

Explore more articles on the latest advancements in medical technology and AI-driven healthcare solutions. Subscribe to our newsletter for regular updates and insights.

0 comments
0 FacebookTwitterPinterestEmail
Health

Trump’s Drug Price Deals: 3-Year Limit Revealed | STAT

by Chief Editor
written by Chief Editor

Trump’s Drug Pricing Deals: A Three-Year Window for Change?

President Trump’s push for lower prescription drug prices, often touted through “most-favored nation” (MFN) deals with pharmaceutical companies, continues to be a subject of scrutiny. Recent Securities and Exchange Commission (SEC) filings reveal a key detail previously undisclosed: at least some of these agreements are set to last for three years.

The “Most Favored Nation” Approach

In late 2020, the Trump administration announced agreements with 16 major drug companies aimed at securing lower prices for Americans. The core idea behind the MFN approach was to leverage the U.S. Market’s size to negotiate prices comparable to those paid by other developed nations. However, the specifics of these deals remained largely opaque, leading to questions about their effectiveness.

Price Hikes Despite Agreements

Despite the fanfare surrounding the deals, price increases persisted in early 2026. An analysis by 46brooklyn revealed that the 16 companies involved raised prices on 872 brand-name drugs in the first two weeks of January 2026, including medications for serious conditions like cancer, heart failure, and Type 2 diabetes. This raised concerns about the actual impact of the agreements.

The Three-Year Timeline

SEC filings, as reported by STAT, indicate that the MFN deals, for at least some drugmakers, have a defined three-year duration. This timeframe provides a clearer picture of the commitment made by both the administration and the pharmaceutical companies. The agreements vary between each of the 16 companies involved.

SEC Shifts Under a Second Trump Administration

The broader regulatory landscape is similarly undergoing significant changes. Following the 2024 election, the Securities and Exchange Commission (SEC) is experiencing a shift in priorities under a Republican-led commission. A key focus is rolling back initiatives from the Biden administration and former Chair Gary Gensler, with an emphasis on facilitating capital formation. An executive order issued in January 2025 initiated a 60-day freeze on rulemaking activity.

Implications for the Future

The three-year timeline for the drug pricing deals suggests a limited window for observing their effects. As the agreements approach their expiration dates, questions arise about potential renewals and the future of the MFN strategy. The SEC’s changing priorities may also influence how pharmaceutical companies are regulated and monitored.

Project Crypto and the SEC

SEC Chairman Paul Atkins has announced the launch of ‘Project Crypto’, aiming to position the U.S. As a leader in the cryptocurrency space. This signals a potential shift in the SEC’s focus and resource allocation, which could indirectly impact oversight of the pharmaceutical industry.

FAQ

Q: What are “most-favored nation” drug pricing deals?
A: These deals aim to secure lower drug prices for Americans by leveraging the U.S. Market’s size to negotiate prices comparable to those paid in other developed countries.

Q: Have drug prices actually decreased as a result of these deals?
A: Despite the agreements, price increases have continued, raising questions about their effectiveness.

Q: How long do these deals last?
A: SEC filings show that, for some companies, the deals are set to last for three years.

Q: What is the SEC’s role in all of this?
A: The SEC is undergoing a shift in priorities under the second Trump administration, with a focus on rolling back regulations and facilitating capital formation.

Did you know? The Trump administration struck deals with 16 pharmaceutical companies in an effort to lower drug prices.

Pro Tip: Stay informed about changes in pharmaceutical regulations by following updates from the SEC and industry news sources.

Wish to learn more about pharmaceutical pricing and regulatory changes? Explore our other articles on healthcare policy and the pharmaceutical industry.

0 comments
0 FacebookTwitterPinterestEmail
Health

This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush

by Chief Editor
written by Chief Editor

The Shifting Sands of the GLP-1 Market: Why Eli Lilly is Surging Ahead

For years, Novo Nordisk’s Ozempic and Wegovy dominated conversations around GLP-1 drugs – a class of medications initially designed for type 2 diabetes, but quickly gaining traction for weight loss. However, the landscape is changing. While Novo Nordisk was the first to market with a GLP-1 drug in 2017, another player has recently taken the lead in this lucrative market.

From Diabetes Treatment to Weight Loss Gold Rush

GLP-1 drugs work by interacting with hormonal pathways involved in digestion, helping to regulate blood sugar and control appetite. Novo Nordisk’s semaglutide is available as Ozempic for type 2 diabetes and Wegovy for obesity. These drugs have shown promise in managing not only diabetes but also conditions like heart disease and potentially even Alzheimer’s disease.

Eli Lilly’s Ascent with Mounjaro and Zepbound

Eli Lilly (NYSE: LLY) is the company making significant inroads. Their drugs, tirzepatide marketed as Mounjaro for type 2 diabetes and Zepbound for weight loss, entered the market later than Novo’s offerings but have quickly gained market share. Currently, Lilly holds 60% of the U.S. Market, while Novo Nordisk’s share has decreased to 39%.

Recent financial reports demonstrate this shift. Lilly reported triple-digit revenue growth for both Mounjaro and Zepbound, collectively generating over $11 billion in revenue in the recent quarter.

Manufacturing and Clinical Trial Success: Key to Lilly’s Growth

A crucial factor in Lilly’s success has been its ability to ramp up manufacturing, ensuring consistent availability of its products. Both semaglutide and tirzepatide experienced shortages in the past, highlighting the importance of reliable supply chains.

a head-to-head study comparing Zepbound and Wegovy revealed that Zepbound facilitated greater weight loss in patients, potentially influencing both patient and physician preferences.

The Pill Factor: A New Convenience

Novo Nordisk recently launched a Wegovy pill, offering a more convenient alternative to injectables. However, Eli Lilly is also developing an oral weight loss candidate currently under regulatory review. Unlike the Wegovy pill, Lilly’s oral option doesn’t require dietary restrictions, potentially making it a more appealing and hassle-free choice for patients.

Potential for Alzheimer’s Treatment Remains

Beyond weight loss and diabetes, research continues to explore the potential of GLP-1 drugs in treating other conditions. Novo Nordisk still believes GLP-1 drugs could be a promising treatment for Alzheimer’s disease, despite recent trial setbacks with similar drugs.

Frequently Asked Questions

What are GLP-1 drugs? GLP-1 drugs are medications that interact with hormonal pathways to regulate blood sugar and appetite, initially developed for type 2 diabetes but also used for weight loss.

What is the difference between Ozempic and Wegovy? Both contain semaglutide, but Ozempic is approved for type 2 diabetes, while Wegovy is approved for obesity.

What is tirzepatide? Tirzepatide is the active ingredient in Eli Lilly’s Mounjaro (for type 2 diabetes) and Zepbound (for weight loss).

Are there any side effects associated with GLP-1 drugs? Lawsuits allege serious side effects, including vision loss, brain dysfunction, and gastrointestinal issues. It’s important to discuss potential risks with a healthcare professional.

Could GLP-1 drugs be used to treat other conditions? Research suggests potential benefits in treating conditions like heart disease, kidney disease, drug addiction, and Alzheimer’s disease.

Pro Tip: Always consult with your doctor before starting any new medication, including GLP-1 drugs, to discuss potential benefits and risks.

Disclaimer: This information is for general knowledge and informational purposes only, and does not constitute medical advice. It’s essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

Explore more articles on pharmaceutical investments and emerging healthcare trends to stay informed about the latest developments in the industry.

0 comments
0 FacebookTwitterPinterestEmail
Health

Novo Nordisk’s New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?

by Chief Editor
written by Chief Editor

Novo Nordisk’s Next Act: Can CagriSema Reclaim GLP-1 Dominance?

Ozempic has been a major growth driver for Novo Nordisk (NYSE: NVO) for years, becoming a household name in the process. However, the Danish drugmaker has recently lost ground to Eli Lilly (NYSE: LLY) in the competitive GLP-1 market. Can Novo Nordisk regain its footing? The answer likely lies in its next-generation therapies, as current product sales are expected to decline this year, according to company guidance.

Introducing CagriSema: A Dual-Action Approach

One of Novo Nordisk’s most promising candidates is CagriSema. This investigational medicine has been gaining attention for its potential to outperform existing GLP-1 drugs. CagriSema is a dual agonist, mimicking the actions of both GLP-1 and amylin – gut hormones that regulate blood sugar and appetite.

Phase 3 Trial Results: CagriSema vs. Semaglutide

Late in 2024, Novo Nordisk announced positive results from a phase 3 weight-loss clinical trial. CagriSema demonstrated superior performance compared to semaglutide (Wegovy for weight loss and Ozempic for diabetes) in overweight or obese patients without type 2 diabetes. After 68 weeks, CagriSema led to a mean weight reduction of 22.7%, compared to 16.1% with Wegovy.

Patient self-administering shot.

CagriSema in Type 2 Diabetes: Another Victory

Novo Nordisk recently shared data from another late-stage study, this time comparing CagriSema to Ozempic in patients with type 2 diabetes who were also overweight or obese. CagriSema resulted in an average 1.91% reduction in blood sugar from baseline (8.2%) and an average weight loss of 14.2%. Again, CagriSema outperformed Ozempic in this trial.

What’s on the Horizon for Novo Nordisk?

Novo Nordisk has already submitted regulatory applications for CagriSema as a weight loss treatment and plans to seek approval for its use in diabetes after completing two additional phase 3 studies, including one focused on cardiovascular outcomes. Wegovy has also recently received label expansions, including for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), which is expected to boost sales.

Manufacturing Challenges and Competition

Despite CagriSema’s promising results, manufacturing complexities and potential costs are concerns. It is expected to be more difficult and expensive to produce than semaglutide, which has previously faced supply constraints. Eli Lilly’s retatrutide, which demonstrated a mean weight loss of up to 28.7% in a phase 3 study, presents a strong competitive challenge.

Is Novo Nordisk a Good Investment?

While Eli Lilly currently appears poised to maintain its lead in the anti-obesity drug market, CagriSema’s superiority to Wegovy and Ozempic should help Novo Nordisk improve its performance, particularly as the company expands its manufacturing capacity. Novo Nordisk also has several other promising diabetes and weight management products in development, including Amycretin, in both oral and subcutaneous formulations.

Frequently Asked Questions (FAQ)

What is CagriSema?
CagriSema is an investigational medicine from Novo Nordisk that mimics the actions of two gut hormones, GLP-1 and amylin, to help regulate blood sugar and appetite.
How does CagriSema compare to Wegovy?
In a phase 3 trial, CagriSema led to a greater mean weight reduction (22.7%) than Wegovy (16.1%) after 68 weeks.
What are the potential challenges for Novo Nordisk?
Manufacturing complexities, higher production costs, and competition from Eli Lilly’s retatrutide are potential challenges.

Don’t miss out! Our analyst team has identified the 10 best stocks for investors to buy now… and Novo Nordisk wasn’t one of them. Discover the stocks that could deliver significant returns in the years ahead!

See the 10 stocks »

*Stock Advisor returns as of February 16, 2026.

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

0 comments
0 FacebookTwitterPinterestEmail
Health

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.

by Chief Editor
written by Chief Editor

The Shifting Sands of the Weight-Loss Market: Opportunities Beyond the GLP-1 Hype

Even as Eli Lilly (NYSE: LLY) currently dominates investor attention with its blockbuster GLP-1 drugs, Mounjaro and Zepbound, a closer look reveals potential opportunities in the stocks of its competitors, Novo Nordisk (NYSE: NVO) and Pfizer (NYSE: PFE). The market isn’t a one-horse race and savvy investors may find value in companies currently facing headwinds.

Lilly’s Momentum: A Premium Priced In

Eli Lilly’s impressive 2025 performance – a 99% sales increase for Mounjaro and a 175% jump for Zepbound – has propelled its stock to a price-to-earnings ratio of 46. This reflects significant investor enthusiasm, but also suggests limited upside for value-focused investors. The dividend yield, at a modest 0.6%, further indicates that much of the potential return is already factored into the share price.

Novo Nordisk: Navigating Challenges and a Pill-Shaped Opportunity

Novo Nordisk, despite experiencing 31% growth in its obesity drug sales in 2025, has seen its stock price suffer. Concerns surrounding a pricing agreement with the U.S. Government are contributing to anticipated weak financial results in 2026. Still, the company’s stock, down 66% since mid-2024, now presents a more attractive valuation with a P/E ratio of 13 and a 3.9% dividend yield, supported by a 40% payout ratio.

Crucially, Novo Nordisk is poised to disrupt the market further with its newly launched GLP-1 pill. This oral formulation could significantly broaden access to weight-loss medication, potentially driving substantial growth in 2027 and beyond.

Pfizer: A Turnaround Story in the Making

Pfizer’s attempt to develop an internally generated GLP-1 drug failed, but the company is actively pursuing partnerships and acquisitions to enter the market. While not currently a leader in this space, Pfizer’s history of pharmaceutical innovation suggests it’s well-positioned to regain ground. Success in oncology and migraine treatments also provides diversification and potential growth avenues.

For investors willing to embrace a turnaround story, Pfizer offers a substantial 6.3% dividend yield. While the payout ratio currently exceeds 100%, the potential for future earnings growth could produce this dividend sustainable.

Understanding the Risks and Rewards

Investing in Novo Nordisk and Pfizer requires a contrarian mindset. Both companies are facing short-term challenges, but their long-term prospects remain promising. The key is to assess whether the current market pessimism has created a buying opportunity.

Pro Tip:

Don’t solely focus on the GLP-1 market. Diversification within the pharmaceutical sector is crucial. Pfizer’s advancements in oncology and migraine treatments offer additional growth potential.

FAQ: Navigating the Weight-Loss Drug Landscape

  • Is Eli Lilly overvalued? Currently, its high P/E ratio suggests limited upside for value investors.
  • What is Novo Nordisk’s biggest advantage? The introduction of an oral GLP-1 pill could significantly expand its market reach.
  • Is Pfizer a risky investment? As a turnaround story, Pfizer carries more risk, but also offers potentially higher rewards.
  • Are dividends sustainable for Novo Nordisk and Pfizer? Novo Nordisk’s dividend is well-covered, while Pfizer’s is currently high but could improve with earnings growth.

Did you understand?

The GLP-1 drug market is expected to reach hundreds of billions of dollars in the coming years, making it one of the most lucrative segments of the pharmaceutical industry.

Before making any investment decisions, consider consulting with a financial advisor and conducting thorough research. The Motley Fool Stock Advisor analyst team has identified their 10 best stocks for investors to buy now, and Pfizer wasn’t one of them.

*Stock Advisor returns as of February 11, 2026.

Reuben Gregg Brewer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Pfizer. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy.

Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip. was originally published by The Motley Fool

0 comments
0 FacebookTwitterPinterestEmail
Health

Hims & Hers cancels plan for Wegovy weight-loss pill knockoff

by Chief Editor
written by Chief Editor

Hims & Hers Retreats from Wegovy Knockoff: A Sign of Things to Reach for Weight-Loss Drugs?

Telehealth company Hims & Hers quickly reversed course on its plan to offer a cheaper, compounded version of Novo Nordisk’s Wegovy weight-loss pill, just days after announcing the product. The move came following threats of a lawsuit from Novo Nordisk and a warning from the Food and Drug Administration (FDA) regarding unapproved compounded drugs. This episode highlights the growing tensions and regulatory scrutiny surrounding the booming market for GLP-1 medications like Wegovy, Ozempic, and Zepbound.

The Rise of Compounded Weight-Loss Drugs and FDA Concerns

For years, Hims & Hers has capitalized on the demand for accessible and affordable medications, initially offering compounded versions of injectable weight-loss drugs. Compounding pharmacies create customized medications by mixing ingredients, often used when a commercially available drug is in short supply. However, the FDA has raised concerns about the quality, safety, and efficacy of these compounded drugs, particularly as approved alternatives become more readily available.

The FDA stated it plans to take “decisive” action against companies selling “illegal copycat drugs,” signaling a crackdown on the practice. While the FDA permits compounding when drugs are officially in shortage, it declared the GLP-1 drug shortage over in 2024. Companies like Hims continued to operate under an exception, claiming prescriptions were customized for individual patients.

Novo Nordisk’s Aggressive Defense of Wegovy

Novo Nordisk, the manufacturer of Wegovy, swiftly responded to Hims’ announcement with a vow to sue, labeling the product an “unapproved, inauthentic, and untested knockoff.” The Danish pharmaceutical giant is heavily invested in protecting its intellectual property and market share, especially with the recent launch of the Wegovy pill – the first oral formulation of the medication. Novo plans to feature Wegovy in a high-profile Super Bowl ad, underscoring its commitment to the drug’s success.

Hims had initially priced its compounded Wegovy pill at $49 per month, significantly undercutting Novo Nordisk’s $149 price tag. This aggressive pricing strategy aimed to attract cost-conscious consumers, but ultimately proved unsustainable in the face of legal and regulatory pressure.

What Does This Mean for the Future of GLP-1 Access?

The Hims & Hers situation points to a potential shift in the landscape of GLP-1 access. While compounded drugs offered a temporary solution for affordability and availability, increased FDA scrutiny suggests these options may become more limited. The focus is likely to shift towards FDA-approved medications, potentially driving up costs for some patients.

Eli Lilly is also expected to enter the oral GLP-1 market with its orforglipron medication, potentially increasing competition and availability. However, the initial focus will be on FDA-approved products, setting a higher standard for safety and efficacy.

The Role of Telehealth Companies in the Weight-Loss Market

Hims & Hers, along with other telehealth companies, have played a significant role in expanding access to weight-loss medications. They offer convenient online consultations and prescription services, appealing to a broad range of patients. However, this episode demonstrates the require for these companies to operate within the bounds of FDA regulations and respect intellectual property rights.

Did you realize? The market for GLP-1 drugs is estimated to be worth billions of dollars, driven by the growing prevalence of obesity and the increasing demand for effective weight-loss treatments.

FAQ

Q: What are GLP-1 drugs?
A: GLP-1 drugs are a class of medications originally developed for treating type 2 diabetes, but have been found to be effective for weight loss.

Q: What is compounding?
A: Compounding is the practice of mixing ingredients to create a customized medication, often used when a commercially available drug is in short supply or needs to be tailored to a patient’s specific needs.

Q: Will the FDA continue to crack down on compounded GLP-1 drugs?
A: The FDA has indicated it will take “decisive” action against companies selling unapproved compounded drugs, suggesting increased enforcement in the future.

Q: What is the difference between Wegovy, Ozempic, and Zepbound?
A: Wegovy and Zepbound are approved for weight loss, while Ozempic is primarily approved for type 2 diabetes, though it is often prescribed off-label for weight loss. All three contain semaglutide or tirzepatide, which are GLP-1 receptor agonists.

Pro Tip: Always consult with a healthcare professional before starting any new medication, including weight-loss drugs. Discuss the potential benefits and risks, and ensure the medication is appropriate for your individual health needs.

Want to learn more about the latest developments in weight-loss treatments? Explore our other articles on GLP-1 medications and obesity management.

0 comments
0 FacebookTwitterPinterestEmail
Newer Posts
Older Posts